459 related articles for article (PubMed ID: 33146388)
1. US rheumatologists' beliefs and knowledge about biosimilars: a survey.
Gibofsky A; McCabe D
Rheumatology (Oxford); 2021 Feb; 60(2):896-901. PubMed ID: 33146388
[TBL] [Abstract][Full Text] [Related]
2. Biosimilars in rheumatology: understanding the rigor of their development.
Goel N; Chance K
Rheumatology (Oxford); 2017 Feb; 56(2):187-197. PubMed ID: 27241704
[TBL] [Abstract][Full Text] [Related]
3. An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars.
Gibofsky A; Jacobson G; Franklin A; O'Hara-Levi S; Peyrin-Biroulet L; McGrath M; McCabe D
J Manag Care Spec Pharm; 2023 Apr; 29(4):343-349. PubMed ID: 36989450
[No Abstract] [Full Text] [Related]
4. Biosimilars in pediatric rheumatology and their introduction into routine care.
Aragon Cuevas O; Hedrich CM
Clin Immunol; 2020 Jul; 216():108447. PubMed ID: 32360950
[TBL] [Abstract][Full Text] [Related]
5. Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey.
Beck M; Michel B; Rybarczyk-Vigouret MC; Levêque D; Sordet C; Sibilia J; Velten M;
BioDrugs; 2016 Dec; 30(6):585-592. PubMed ID: 27848166
[TBL] [Abstract][Full Text] [Related]
6. Embracing Change: An International Survey Study on the Beliefs and Attitudes of Pediatric Rheumatologists Towards Biosimilars.
Demirkan FG; Sönmez HE; Lamot L; Akgün Ö; Sözeri B; Ayaz NA;
BioDrugs; 2022 May; 36(3):421-430. PubMed ID: 35380389
[TBL] [Abstract][Full Text] [Related]
7. Era of biosimilars in rheumatology: reshaping the healthcare environment.
Smolen JS; Goncalves J; Quinn M; Benedetti F; Lee JY
RMD Open; 2019; 5(1):e000900. PubMed ID: 31245050
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.
Schulze-Koops H; Skapenko A
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv30-iv48. PubMed ID: 28903543
[TBL] [Abstract][Full Text] [Related]
9. Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.
van Overbeeke E; De Beleyr B; de Hoon J; Westhovens R; Huys I
BioDrugs; 2017 Oct; 31(5):447-459. PubMed ID: 28929342
[TBL] [Abstract][Full Text] [Related]
10. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch.
Sagi S; Anjaneya P; Kalsekar S; Kottke A; Cohen HP
Drug Saf; 2023 Dec; 46(12):1391-1404. PubMed ID: 37902937
[TBL] [Abstract][Full Text] [Related]
12. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.
Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
Am J Clin Dermatol; 2020 Aug; 21(4):483-491. PubMed ID: 32048187
[TBL] [Abstract][Full Text] [Related]
13. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
14. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.
Uhlig T; Goll GL
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv49-iv62. PubMed ID: 28903542
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars in rheumatology.
Araújo FC; Gonçalves J; Fonseca JE
Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
[TBL] [Abstract][Full Text] [Related]
16. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians.
Cohen H; Beydoun D; Chien D; Lessor T; McCabe D; Muenzberg M; Popovian R; Uy J
Adv Ther; 2017 Jan; 33(12):2160-2172. PubMed ID: 27798772
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis.
Komaki Y; Yamada A; Komaki F; Kudaravalli P; Micic D; Ido A; Sakuraba A
J Autoimmun; 2017 May; 79():4-16. PubMed ID: 28209290
[TBL] [Abstract][Full Text] [Related]
18. Patients' information and perspectives on biosimilars in rheumatology: A French nation-wide survey.
Frantzen L; Cohen JD; Tropé S; Beck M; Munos A; Sittler MA; Diebolt R; Metzler I; Sordet C
Joint Bone Spine; 2019 Jul; 86(4):491-496. PubMed ID: 30659920
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]